Overview

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Status:
Active, not recruiting

Trial end date:
2022-04-27

Target enrollment:

Participant gender:

Summary

A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with AML who are ineligible for intensive chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Azacitidine
Decitabine
Venetoclax